

AD_____

Award Number: DAMD17-03-1-0472

TITLE: Nuclear Receptor Interactions in Breast Cancer: The Role of Kinase Signaling Pathways

PRINCIPAL INVESTIGATOR: Filippa Pettersson, Ph.D.

CONTRACTING ORGANIZATION: McGill University
Montreal, QC, H3T 1E2

REPORT DATE: July 2006

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-07-2006		2. REPORT TYPE Annual Summary		3. DATES COVERED (From - To) 1 JUL 2003 - 30 JUN 2006	
4. TITLE AND SUBTITLE Nuclear Receptor Interactions in Breast Cancer: The Role of Kinase Signaling Pathways				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER DAMD17-03-1-0472	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Filippa Pettersson, Ph.D. E-Mail: filippa.pettersson@mail.mcgill.ca				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) McGill University Montreal, QC, H3T 1E2				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT: Retinoids and rexinoids are vitamin A derivatives, which cause growth inhibition and/or apoptosis in various cell types, including some breast cancer cells. Retinoids bind and activate the nuclear receptor RAR, whereas rexinoids specifically bind to the related receptor RXR. While retinoids like RA inhibit the growth of estrogen receptor (ER) positive and not ER negative breast cancer cells, rexinoids appear to have activity in both ER positive and ER negative models. In addition, it has been reported that the rexinoid bexarotene can prevent the development of multidrug resistance following exposure to chemotherapy agents. In this report I describe studies of the interactions of different nuclear receptors in breast cancer cells. I have studied how expression of ER affects the phosphorylation status and activity of RAR α , and found that reexpression of either ER α or β increases phosphorylation of RAR α and also increases the activity of MAPK and PKC pathways. I have also studied how rexinoids modulate the activity of the SXR/RXR heterodimer, and have found that several rexinoids suppress activation of SXR by SXR agonist such as Rifampicin and the chemotherapeutic agent Taxol, which may provide a mechanism to explain how rexinoids can prevent the development of drug resistance.					
15. SUBJECT TERMS Retinoic acid, rexinoids, estrogen receptor, RAR, RXR, SXR, chemotherapy resistance.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	9	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....

SF 298.....2

Table of contents.....3

Introduction.....4

Body.....4

Key Research Accomplishments.....6

Reportable Outcomes.....6

Conclusions.....6

References.....6

Appendices.....7

Introduction

Retinoids are derivatives of vitamin A, which induce differentiation and growth inhibition in a variety of cell types, including breast cancer cells [1-3]. They act mainly by binding to nuclear retinoid receptors, RARs and RXRs, which act as ligand regulated transcription factors [4]. Several natural and synthetic retinoids can inhibit the development of mammary tumors and cause regression of established tumors in rats [5, 6], and there is some clinical evidence that retinoids may be beneficial in breast cancer prevention [7, 8]. Thus, further studies of the potential use of retinoids in therapy of breast cancer are warranted and for this purpose it is important to clarify how retinoids exert their effects on breast cancer cells and what determines sensitivity vs. resistance to these compounds. There is considerable evidence of crosstalk between retinoid signaling and signal transduction pathways activated by growth factors as well as stress stimuli. For example, we have reported that several PKC inhibitors strongly potentiate the response of MDA-MB-231 to RA, and that this involves regulation of PKC δ in particular, as well as *activation* of ERK [9]. Synthetic “rexinoids” (RXR selective retinoid) such as bexarotene (TargretinTM) also have documented antitumor activity in several models of both estrogen receptor (ER) positive and ER negative mammary carcinoma [10-13]. Of note, it has been reported that bexarotene can prevent the development of multidrug resistance following exposure to chemotherapy agents such as Taxol, Cisplatin and Doxorubicin [14-16].

In the first two years of this award, I focused my studies on 1) defining the signal transduction pathways whereby inhibitors of PKC restore sensitivity to retinoids in ER-negative cells and 2) testing the hypothesis that expression of ER alters the phosphorylation status of RAR and/or RXR, thereby rendering the cells sensitive to RA, as described in the approved Statement of Work. Task 1 was fully completed and the results published [9]. Task 2 was partially completed, but the experimental results were less promising. In fact, the hypothesis stated was not supported and my studies of interactions between RAR and ER were not continued. In the third and final year of the award, I have thus refocused my studies on interactions of two other nuclear receptors and their ligands: RXR and SXR (hPXR). SXR is a receptor that is bound and activated by a wide variety of drugs, including Taxol and Cisplatin, and it plays a crucial role in drug metabolism and transport [17-21]. SXR target genes include MDR1, MRP2 and MRP3, as well as several cytochrome P450 enzymes [19, 22-25], and it has been suggested that it may play a role in tumor drug resistance by increasing both the metabolic breakdown and the efflux of drugs like Taxol [19]. Since the transcriptional activity of SXR depends on heterodimerization with RXR [18], I hypothesised that rexinoids may prevent the development of multidrug resistance (see above [14-16]) by interfering with SXR activation by e.g. Taxol.

In this annual report, I will summarize results obtained from studies of the phosphorylation status of RAR α . I will also present results showing that rexinoids can suppress activation of SXR by the strong SXR agonist Rifampicin, as well as by Taxol.

Body/Results

1) Stable expression of ER α or β increases basal phosphorylation of RAR α .

We had observed that the ER positive and RA sensitive cell line MCF-7 displays less basal phosphorylation of RAR α , and also lower PKC activity than the ER negative and RA resistant MDA-MB-231. I thus wanted to assess RAR α phosphorylation in MDA-MB-231 stably expressing ER. I used S30 cells, which stably express ER α [26], and a cell line established in our lab, which stably expresses ER β [27]. The phosphorylation status of RAR α was tested by transfecting the cells with Flag-RAR α , labeling *in vivo* with ³²P-orthophosphate, extracting proteins, and immuno-precipitating the labeled Flag-RAR α using anti-Flag-resin (Sigma). Precipitated proteins were separated on a polyacrylamide gel and visualized

using autoradiography. In contrast to the hypothesis, I found that both S30 and ER β cells displayed *increased* basal phosphorylation of RAR α . In addition, these cells displayed slightly enhanced PKC and MAPK activities, compared to the parental MDA-MB-231. Thus, the increased RA-responsiveness seen in these cells [27-29] is *not* dependent on suppression of these pathways, and clearly different from the effect observed with PKC inhibitors, which resensitize both MDA-MB-231 and MDA-MB-468 to the growth inhibitory effects of RA.

2) Rexinoids suppress activation of SXR.

To begin to examine whether rexinoids can modulate the transcriptional activity of SXR, I transiently transfected LS180 colon cancer cells with the reporter plasmid β DR4(3)-tk-luc, containing a consensus SXR response element (SXRE) [18]. LS180 were chosen since they express relatively high levels of SXR and the induction of SXR target genes by rifampicin (a potent SXR agonist) and Taxol has been well characterized in these cells [19, 23, 30]. Four different rexinoids (bexarotene, LGD1305, 9cisRA, and LGD268) induced a weak activation of the β DR4 reporter. However, when given in combination with rifampicin, the rexinoids suppressed activation caused by the SXR ligand, indicating an antagonistic function. In contrast, an RAR selective retinoid (TTNPB) neither activated the SXRE reporter, nor suppressed activation by rifampicin. The rexinoids also suppressed rifampicin-induced transcription of CYP3A4-XREM-luc, which contains the proximal and the distal SXREs of the CYP3A4 promoter [31], indicating a general effect on SXRE containing promoters (data not shown).

It has been reported that breast tumors and cell lines express SXR [32], suggesting that SXR may play a role in chemoresistance in these tumors. I therefore tested the activation of β DR4(3)-tk-luc in MDA-MB-231 and MCF-7 breast cancer cells by bexarotene, rifampicin and Taxol. I found that activation of the reporter by SXR agonists was more potent in MCF-7 than in MDA-MB-231 (10-12 fold vs. 2-3 fold by 5 μ M Rifampicin), and therefore chose MCF-7 as my breast cancer model. These cells were shown to express SXR, but at a lower level than LS180 or HepG2 hepatoma cells (Figure 1). I found that, as in LS180, bexarotene weakly activated transcription in MCF-7 cells, but suppressed activation in response to both rifampicin and Taxol (Figure 2a-b). To confirm that regulation of reporter activity was indeed dependent on SXR, I transfected the cells with β DR4(3)-tk-luc in the presence of either empty pCMX or pCMX-SXR. In the absence of pCMX-SXR, no or very weak activation of this reporter was observed (Figure 2c). No change in renilla luciferase activity produced by the control vector pRL-CMV was seen in response to any of the treatments, indicating lack of non-specific promoter regulation (Figure 2d).

I then tested if bexarotene could suppress the induction of the SXR target gene MDR1/Pgp by rifampicin and Taxol. Western blot analysis of membrane protein fractions showed that both SXR agonists upregulated Pgp in LS180 cells, as previously reported [19, 22]. Further, bexarotene was shown to induce Pgp, but *reduce* the induction by rifampicin and Taxol (Figure 3a), supporting data from transient transfection assays. In MCF-7 cells, flow cytometry was used to determine Pgp levels, since I had difficulty detecting Pgp by Western analysis in these cells. Results confirmed that bexarotene suppressed induction of endogenous MDR1/Pgp by rifampicin (Figure 3b). It is thus feasible that bexarotene, and perhaps other rexinoids, may suppress the induction of drug resistance at least partially by reducing the activation of SXR and the induction of its target genes.

To determine if rexinoid suppression of transcription was associated with reduced binding of SXR/RXR to DNA, gel shift analyses were performed, assessing binding of nuclear proteins to the β DR4 element [33] as well as the ER6 element present in the CYP3A4 promoter (proximal SXRE [25]). Nuclear extracts from MCF-7 cells treated with rifampicin, bexarotene or both were used. I observed increased binding in the presence of rifampicin, while this effect was reduced by bexarotene (Figure 4 a-b). Supershift analysis with RXR and SXR specific antibodies indicated that both receptors are presents in the major complex binding to the SXRE (not shown). Gel shift analysis using *in vitro* translated proteins confirmed that both receptors were required for binding, and also showed that neither drug affects binding of the heterodimer to the SXRE *in vitro* (Figure 4c). This excludes the possibility of the rexinoid having a direct effect on *e.g.* receptor conformation that reduces its ability to bind the SXRE. Instead, I propose that bexarotene may

cause either a reduction in total receptor levels and/or may induce posttranslational changes that inhibit the ability of SXR and RXR to bind to each other or to transcriptional co-factors needed for optimal activation.

List of Key Research Accomplishments

- * Completed the majority of tasks described in the original Statement of Work. Disproved hypothesis stated in Task 2.
- * Showed that rexinoids (RXR ligands) can suppress the activation of SXR by the antibiotic rifampicin as well as the chemotherapeutic drug Taxol.
- * Showed that bexarotene can suppress induction of the SXR target gene MDR1/Pgp by rifampicin and Taxol.
- * Showed that bexarotene reduces the binding of nuclear proteins (SXR and RXR) to SXR response elements.

Reportable outcomes

Abstracts and presentations:

Filippa Pettersson, Nessrine Hanna, Oanh Le, Marina Lagodich, and Wilson, H Miller, Jr. *Rexinoids suppress activation of SXR by SXR agonists rifampicin and paclitaxel in human tumor cells*. Poster, Keystone Symposia, Nuclear Receptors: Orphan Brothers, Banff, March 2006.

Filippa Pettersson, Nessrine Hanna, Marina Lagodich, and Wilson, H Miller, Jr. *Rexinoids Suppress Activation of SXR in Human Tumor Cells: Potential Role in Multidrug Resistance*. Short talk, Canadian Breast Cancer Research Alliance, Reasons for Hope Fourth Scientific Conference, Montreal, May 2006.

Conclusions

During the third and final year of this award, I have completed most of the tasks presented in the original Statement of Work. Notably, experiments performed in relation to Task 2 failed to support the hypothesis stated, and studies were not continued beyond task 2d.

In addition, I made considerable progress elucidating a negative regulation of SXR by ligands of its heterodimer partner RXR, rexinoids. This may partially explain the ability of bexarotene to prevent or reduce the development of drug resistance in tumors treated with chemotherapeutic drugs like Taxol, which are known activators of SXR.

References

1. Rubin, M., et al., *9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein*. Cancer Research, 1994. **54**(24): p. 6549-6556.
2. Mangiarotti, R., M. Danova, and C. Alberici, *All-trans retinoic acid (ATRA)-induced apoptosis is preceded by G1 arrest in human MCF-7 breast cancer cells*. Br J Cancer, 1998. **77**(2): p. 186-191.
3. Zhu, W.Y., et al., *Retinoic acid inhibition of cell cycle progression in MCF-7 human breast cancer cells*. Exp. Cell Res, 1997. **234**(2): p. 293-299.
4. Evans, R.M., *The steroid and thyroid hormone receptor superfamily*. Science, 1988. **240**: p. 889-895.
5. Gottardis, M.M., et al., *The efficacy of 9-cis retinoic acid in experimental models of cancer*. Breast Cancer Res Treat, 1996. **38**(1): p. 85-96.
6. Thompson, H.J., et al., *Inhibition of 1-methyl-1-nitrosourea-induced mammary carcinogenesis in the rat by the retinoid axerophthene*. Arzneimittelforschung, 1980. **30**(7): p. 1127-1129.
7. Hunter, D.J., et al., *A prospective study of the intake of vitamins C, E, and A and the risk of breast cancer*. N Engl J Med, 1993. **329**(4): p. 234-240.

8. Veronesi, U., et al., *Chemoprevention of breast cancer with fenretinide*. IARC.Sci Publ., 1996(136): p. 87-94.
9. Pettersson, F., et al., *Enhanced retinoid induced apoptosis in MDA-MB-231 breast cancer cells involves activation of ERK*. Oncogene, 2004. **23**(42): p. 7053-7066.
10. Bischoff, E.D., et al., *Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma*. Cancer Res, 1998. **58**(3): p. 479-484.
11. Gottardis, M.M., et al., *Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand*. Cancer Res, 1996. **56**(24): p. 5566-5570.
12. Wu, K., et al., *Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069*. Cancer Epidemiol Biomarkers Prev, 2002. **11**(5): p. 467-74.
13. Wu, K., et al., *The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice*. Cancer Res, 2002. **62**(22): p. 6376-80.
14. Yen, W.C., et al., *A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer*. Clin Cancer Res, 2004. **10**(24): p. 8656-64.
15. Yen, W.C. and W.W. Lamph, *The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma*. Mol Cancer Ther, 2005. **4**(5): p. 824-34.
16. Yen, W.C., R.Y. Prudente, and W.W. Lamph, *Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma*. Breast Cancer Res Treat, 2004. **88**(2): p. 141-8.
17. Lehmann, J.M., et al., *The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions*. J Clin Invest, 1998. **102**(5): p. 1016-23.
18. Blumberg, B., et al., *SXR, a novel steroid and xenobiotic-sensing nuclear receptor*. Genes Dev, 1998. **12**(20): p. 3195-205.
19. Synold, T.W., I. Dussault, and B.M. Forman, *The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux*. Nat Med, 2001. **7**(5): p. 584-90.
20. Takami, N., H. Sakamoto, and T. Yamamoto, *Steroid and xenobiotic receptor (SXR) is a key system for the acquisition of cisplatin resistance in endometrial cancer cells*. J Int Med Res, 2003. **31**(2): p. 59-68.
21. Masuyama, H., et al., *The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion*. Mol Endocrinol, 2005. **19**(5): p. 1170-80.
22. Geick, A., M. Eichelbaum, and O. Burk, *Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin*. J Biol Chem, 2001. **276**(18): p. 14581-7.
23. Kast, H.R., et al., *Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor*. J Biol Chem, 2002. **277**(4): p. 2908-15.
24. Teng, S., V. Jekerle, and M. Piquette-Miller, *Induction of ABCC3 (MRP3) by pregnane X receptor activators*. Drug Metab Dispos, 2003. **31**(11): p. 1296-9.
25. Goodwin, B., E. Hodgson, and C. Liddle, *The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module*. Mol Pharmacol, 1999. **56**(6): p. 1329-39.
26. Jiang, S. and V.C. Jordan, *Growth regulation of estrogen-receptor negative human breast carcinoma cells transfected with complementary DNAs for estrogen receptor*. J Natl Cancer Inst, 1992. **84**: p. 580-591.
27. Rousseau, C., et al., *ERbeta sensitizes breast cancer cells to retinoic acid: Evidence of transcriptional cross-talk*. Mol Cancer Res, 2004. **2**: p. 523-531.
28. Rosenauer, A., et al., *Estrogen receptor expression activates the transcriptional and growth-inhibitory response to retinoids without enhanced retinoic acid receptor alpha expression*. Cancer Research, 1998. **58**(22): p. 5110-5116.
29. Rousseau, C., et al., *The N-terminal of the estrogen receptor (ERalpha) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells*. J Steroid Biochem Mol Biol, 2003. **86**(1): p. 1-14.
30. Pfrunder, A., et al., *Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines*. J Pharm Pharmacol, 2003. **55**(1): p. 59-66.
31. Tirona, R.G., et al., *The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4*. Nat Med, 2003. **9**(2): p. 220-4.
32. Dotzlaw, H., et al., *The human orphan receptor PXR messenger RNA is expressed in both normal*
33. Perlmann, T., et al., *Determinants for selective RAR and TR recognition of direct repeat HREs*. Genes Dev, 1993. **7**(7B): p. 1411-22.

Appendices

Figures, 2 pages.

APPENDIX: Figures





Figure 1. MCF-7 cells express SXR. SXR and β-actin levels were determined by semi-quantitative RT-PCR






Figure 3. Bexarotene suppresses induction of Pgp. Cells were treated for 48 h with 5 μ M rifampicin or Taxol and 1 μ M bexarotene. **a)** Membrane fractions were isolated from LS180 cells and protein levels were analyzed by Western blot. Values indicated are arbitrary units determined by densitometry. As a control for gel loading, Ponceau S staining of the membrane showed equal amounts of total protein. **b)** MCF-7 cells were stained with a FITC labeled Pgp antibody. Pgp positive cells were detected by flow cytometry and numbers shown are percent positive cells compared to the negative control (FITC-mouse IgG, white histogram).




Figure 4. Bexarotene reduces rifampicin-induced binding of nuclear proteins to SXREs. Nuclear extracts from MCF-7, treated as indicated for 24 hours, were incubated with [32 P] end-labeled oligonucleotides comprising the β DR4 element (**a**) and the CYP3A4 proximal SXRE element (**b**) and protein/DNA complexes were separated by polyacrylamide gel electrophoresis. **c)** *In vitro* translated SXR and RXR were incubated with [32 P] end-labeled β DR4 in the presence or absence of the drugs indicated.